NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TRIB
Trinity Biotech plc
There isn't enough reported data to score TRIB yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TRIB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
TRIB's revenue, profitability, cash flow and balance sheet are all currently under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TRIB PE Valuation
TRIB has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TRIB Forward outlook
There aren't enough analyst estimates for TRIB to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus TRIB down 174%.
TRIB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$60.60 | +$21.54 |
| Q3 2025 | -$68.28 | -$0.42 |
| Q2 2025 | -$73.86 | +$6.60 |
| Q1 2025 | -$85.44 | -$2.88 |
| Q4 2024 | -$82.14 | +$14.16 |
| Q3 2024 | -$67.86 | +$46.44 |
| Q2 2024 | -$80.46 | +$42.54 |
| Q1 2024 | -$82.56 | +$113.04 |
TRIB is still losing money, but far less than before: $60.60 per share over the past year, against $195.60 at its worst in early 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 30% for TRIB.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
TRIB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $11.1M | -30% |
| Q3 2025 | $14.2M | -6% |
| Q2 2025 | $11M | -31% |
| Q1 2025 | $7.6M | -48% |
| Q4 2024 | $15.9M | +18% |
| Q3 2024 | $15.2M | +3.2% |
| Q2 2024 | $15.8M | +14% |
| Q1 2024 | $14.7M | -0.8% |
TRIB's revenue has slid since its 2020 peak: $11M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -27% | +46 points |
| Q3 2025 | -3.8% | +13 points |
| Q2 2025 | -28% | -2.2 points |
| Q1 2025 | -62% | -42 points |
| Q4 2024 | -73% | -47 points |
| Q3 2024 | -17% | +14 points |
| Q2 2024 | -26% | +81 points |
| Q1 2024 | -21% | +5.8 points |
TRIB's operating margin was −27% last quarter, up 46 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
TRIB has the stronger cash trend. Its trailing FCF is up 4.7% versus its history, compared with NVO at down 14%.
TRIB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.5M | -351% |
| Q3 2025 | -$77.1K | +$6.2M |
| Q2 2025 | -$1.7M | +$2.6M |
| Q1 2025 | -$3M | +$3.3M |
| Q4 2024 | $615K | +$2.5M |
| Q3 2024 | -$6.3M | -$1M |
| Q2 2024 | -$4.3M | +$715K |
| Q1 2024 | -$6.3M | -$2.9M |
TRIB has burned cash in most quarters: −$6M over the past year, against −$16M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TRIB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TRIB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -950 shares |
| 1 year | +31% | +148K shares |
| 3 years | +144% | +367K shares |
| 5 years | +249% | +443K shares |
| Available history | +266% | +451K shares |
TRIB has 620,900 diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $270,000 |
| Q1 2024 | — |
TRIB hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TRIB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 12.0x | High |
| Q4 2021 | 7.5x | High |
| Q3 2021 | 16.9x | High |
| Q2 2021 | 5.2x | High |
| Q1 2021 | 11.4x | High |
| Q4 2020 | 24.1x | High |
| Q3 2020 | 3.5x | Elevated |
| Q2 2020 | 6.5x | High |
TRIB's net debt is about 12 years of its operating earnings (EBITDA), up from 11 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TRIB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.6 | Neutral |
| Stochastic | 10.5 | Oversold |
TRIB's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRIB PE vs Healthcare Sector
TRIB has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has stronger trend alignment. NVO is above 1 of 5 weekly averages versus TRIB above 0 of 3.
TRIB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.56 | 10% below |
| 20 week MA | $8.71 | 32% below |
| 50 week MA | $16.5 | 64% below |
TRIB is in a downtrend: it's below all three of its weekly moving averages, and 64% below its 50-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over TRIB on returns for 2026, with the stronger performance.
TRIB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $43.8 | $30.0 | -32% |
| 2026 YTD | $30.0 | $5.88 | -80% |
TRIB has finished every year since 2025 lower, and it's down 80% so far in 2026.